MPT comparisons: treatment durations and crossover therapy
| Trial . | Response at 6 to 18 mo, % . | PFS median, mo . | Duration of induction MP and MPT, mo . | Thalidomide maintenance . | Thalidomide at relapse for MP . | Median overall survival for MPT, mo . | ||
|---|---|---|---|---|---|---|---|---|
| ≥ PR . | ≥ VGPR . | MPT . | MP . | |||||
| Italian (ages < 65 and > 75) | ||||||||
| Palumbo et al | 68.9 | 44.9 | 24.7 | 15 | 6 (6 × 4-wk cycles) | Yes, ongoing for MPT arm | Yes (41.5%)* | 45.0 (vs 47.6) |
| French (IFM) | ||||||||
| Facon et al2 (age 65 = 75) | 76 | 47 | 27.5 | 17.8 | 18 (12 × 6-wk cycles) | No | Yes (44%) | 51.6 (vs 33.2) |
| Hulin et al3 (age ≥ 75) | 62 | 22 | 24.1 | 19 | 18 (12 × 6-wk cycles) | No | Yes (77%) | 45.3 (vs 27.7) |
| Trial . | Response at 6 to 18 mo, % . | PFS median, mo . | Duration of induction MP and MPT, mo . | Thalidomide maintenance . | Thalidomide at relapse for MP . | Median overall survival for MPT, mo . | ||
|---|---|---|---|---|---|---|---|---|
| ≥ PR . | ≥ VGPR . | MPT . | MP . | |||||
| Italian (ages < 65 and > 75) | ||||||||
| Palumbo et al | 68.9 | 44.9 | 24.7 | 15 | 6 (6 × 4-wk cycles) | Yes, ongoing for MPT arm | Yes (41.5%)* | 45.0 (vs 47.6) |
| French (IFM) | ||||||||
| Facon et al2 (age 65 = 75) | 76 | 47 | 27.5 | 17.8 | 18 (12 × 6-wk cycles) | No | Yes (44%) | 51.6 (vs 33.2) |
| Hulin et al3 (age ≥ 75) | 62 | 22 | 24.1 | 19 | 18 (12 × 6-wk cycles) | No | Yes (77%) | 45.3 (vs 27.7) |
Thalidomide and bortezomib combinations used.